The co‐formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta‐analysis of phase III studies in patients with type 2 diabetes

AIMS: To investigate whether the proven benefits of insulin degludec (IDeg) combined with insulin aspart (IAsp), known as IDegAsp, given twice daily, extend across a wide spectrum of patients with diabetes. MATERIALS AND METHODS: This was a post hoc pooled analysis of 5 phase III randomized, 26‐week...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Diabetes Obes Metab
Autores principales: Haluzík, Martin, Fulcher, Greg, Pieber, Thomas R., Bardtrum, Lars, Tutkunkardas, Deniz, Rodbard, Helena W.
Formato: Artigo
Lenguaje:Inglês
Publicado: Blackwell Publishing Ltd 2018
Materias:
Original Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6033009/
https://ncbi.nlm.nih.gov/pubmed/29451706
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13261
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares